• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Is the ship really sinking?









Just curious to the state of Astellas? How morale? I heard Vesicare is going generic 2018/2019.

Overall, morale at Astellas is good. Some things are changing, but so far the changes have been mostly positive.

Vesicare will face generic competition in mid-2019 at the earliest. The exact date is unknown. But we have some exciting pipeline compounds that will hopefully launch soon.
 




Get rid of several toxic ASD’s and culture will begin to return. Lynn, David and Kevin are good people, hopefully they recognize what we out here in the field see.
 




“We have some exciting compounds that will hopefly.....”

other famous last words from PARROITS:

Go for Throttle up

Captain Smith we’re about to hit an iceburg
Overall, morale at Astellas is good. Some things are changing, but so far the changes have been mostly positive.

Vesicare will face generic competition in mid-2019 at the earliest. The exact date is unknown. But we have some exciting pipeline compounds that will hopefully launch soon.